Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT04523194
Active, not recruiting Observational

Massachusetts General Hospital and Tsuchiura Kyodo General Hospital Coronary Imaging Collaboration

NCT04523194 · tracked via the Priya Life Science Japan tracker
Sponsor
Massachusetts General Hospital
Phase
Observational
Started
2020-11-09
Last updated
2025-12-29

Condition(s) studied

Atherosclerosis

Investigational drug(s) / intervention(s)

Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA)

Optical Coherence Tomography (OCT) and Computed Tomography Angiography (CTA): Subjects underwent CTA, then OCT during cardiac catheterization as part of their standard clinical care.

Study summary

The purpose of this collaboration is to establish a multi-modality image database including coronary angiograms, optical coherence tomography (OCT), computed tomography angiograms (CTA) and cardiac magnetic resonance imaging (CMR) for future studies. The main goal of this collaboration is to create a resource to promote further understanding of the pathobiology of atherosclerosis through image analysis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Had CTA prior to cardiac catheterization and then OCT during catheterization Exclusion Criteria: \-

Primary outcome measure(s)

  • Major Adverse Cardiac Events (MACE) — 1 Year
    MACE

Trial sites (2)

FacilityCityRegionStatus
Massachusetts General Hospital Boston Massachusetts
Tsuchiura Kyodo General Hospital Tsuchiura Japan

More Massachusetts General Hospital trials in Japan

A Global Study of the PETAL Consortium Recruiting

Other trials for the same condition

Guideline Oriented Approach To Lipid Lowering In Asia-Pacific Recruiting
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04523194 on ClinicalTrials.gov ↗ ← All trials in Japan